Data / Form D filings / FlightPath Biosciences, Inc.
FlightPath Biosciences, Inc.: Form D filings
FlightPath Biosciences, Inc., a biotechnology company in Birmingham, MI, filed 4 Form D notices with the SEC between 2020 and 2024. The latest, on October 24, 2024, reports $8.1 million sold of a $9 million offering to 17 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 15 Fairfax Street, Birmingham, MI, 48009
- Phone
- (415) 530-1828
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2019
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1809914
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Oct 24, 2024 | Amendment | $9,000,000 | $8,064,826 | $935,174 | 17 | Feb 13, 2023 | sec.gov |
| Feb 15, 2023 | New notice | $8,000,000 | $1,100,000 | $6,900,000 | 6 | Feb 13, 2023 | sec.gov |
| Dec 16, 2021 | Amendment | $5,000,000 | $1,522,000 | $3,478,000 | 1 | Feb 12, 2020 | sec.gov |
| Apr 17, 2020 | New notice | $5,000,000 | $350,000 | $4,650,000 | 1 | Feb 12, 2020 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Curtis Scribner | Director | |
| Matthew Tindall | Executive Officer, Director | |
| Cristina Larkin | Director |
Other biotechnology companies in Michigan that filed recently
- Dvant Pharma, Inc. $1.2 million · Oct 13, 2026
- iReprogram, Inc offering · Aug 13, 2026
Every Form D from the week of Oct 21, 2024 · All recent filings in Michigan · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what FlightPath Biosciences, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.